Sunday, 20 September 2020


Daiichi Sankyo receives regulatory approval for hypertension tablets

10 January 2019 | News

This approval allows for the marketing of MINNEBRO for this indication within Japan.

Image credit- isorepublic.com

Image credit- isorepublic.com

Exelixis, Inc. has announced that its partner Daiichi Sankyo Company, Limited received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for esaxerenone tablets, MINNEBRO 1.25 mg, 2.5 mg, and 5 mg, as a treatment for patients with hypertension.

This approval allows for the marketing of MINNEBRO for this indication within Japan. MINNEBRO is a compound identified during the prior research collaboration between Exelixis and Daiichi Sankyo, which the companies entered into in March 2006, and has been subsequently developed by Daiichi Sankyo.

“The approval of MINNEBRO brings an important new therapeutic option to clinicians in Japan. It also marks a significant scientific milestone for Exelixis, joining cabozantinib and cobimetinib as the third molecule from our discovery efforts to receive regulatory approval,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls